Gejing Deng
Sanofi (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Monoclonal and Polyclonal Antibodies Research, Glioma Diagnosis and Treatment, Aquaculture Nutrition and Growth, Ubiquitin and proteasome pathways
Most-Cited Works
- → Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion(2015)442 cited
- → Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques(2017)268 cited
- → Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation(2019)243 cited
- → Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition(2017)160 cited
- → A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells(2022)147 cited
- → Amino acid sequence of a new type of antifreeze protein, from the longhorn sculpin Myoxocephalus octodecimspinosis(1997)143 cited
- → Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule(2014)137 cited
- → Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection(2012)116 cited
- → Applications of mass spectrometry in early stages of target based drug discovery(2005)87 cited
- → Lys6-modified Ubiquitin Inhibits Ubiquitin-dependent Protein Degradation(2005)86 cited